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The effect of forskolin on cGMP regulation was investigated using dispersed rat pinealocytes. Forskolin stimulated 
cGMP accumulation i a concentration-dependent manner; this response was strongly potentiated by an cq-adrenergic 
[Ca2+]~ mechanism involving protein kinase C. These findings provide further evidence that activation of two receptor- 
regulated signal transduction mechanisms may be commonly required for maximal stimulation of cGMP accumulation, 
and establish anew experimental pproach to the study ofcGMP regulation. 
Forskolin; cyclic GMP; Guanylyl cyclase; Protein kinase C; Ca2+; (Pineal) 
1. INTRODUCTION 
Activation of biochemical 'AND' gates [The 
term biochemical AND gate describes regulatory 
mechanisms which require that two independent 
receptor-regulated processes must act simulta- 
neously to produce a full response. This is ana- 
logous to the electronic AND gate which requires 
that two electronic signals must be received simul- 
taneously for an output signal to be generated.] 
generates large and highly selective changes in 
cytosolic oncentrations of cyclic nucleotides [1-5]. 
Examples come from the rat pinealocyte where 
norepinephrine (NE) stimulates cAMP and cGMP 
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accumulation by concurrent activation of al- and 
fl-adrenoceptors [1]. fl-Adrenoceptor activation 
produces an increase of 7-10-fold in cAMP and of 
2-4- fold in cGMP. Selective O~l-adrenoceptor 
stimulation alone has no effect on cAMP or 
cGMP, but potentiates fl-adrenergic stimulation of 
cAMP by about 10-fold and/]-adrenergic stimula- 
tion of cGMP about 50-100-fold [6]. These in- 
teractions generate > 100-fold increases in 
pinealocyte cyclic nucleotides. 
The post-receptor mechanism involved in the 
otl-adrenergic potentiation of/~-adrenergic stimula- 
tion of cAMP and cGMP appears to involve 
al-adrenergic activation of both Ca2+/phospho - 
lipid-dependent protein kinase C (PKC) [7,8] and 
elevation of intracellular Ca 2+ ([CA2+]i) [9,10]. 
The available evidence suggests that interaction 
between PKC and Ca 2+ may act in part to enhance 
activation of cyclases by direct phosphorylation 
[11-14]. In the case of cGMP, the potentiation 
mechanism also requires a distinct second Ca 2+- 
dependent event [10]. 
Here, we have extended our investigation of the 
control of pinealocyte cGMP using forskolin (FSK) 
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[15,16], which has the well documented action of 
directly activating adenylyl cyclase and elevating 
cAMP. As a result, a conceptual FSK = cAMP 
equation has evolved, reflecting the widespread 
belief that FSK modifies cellular physiology 
through cAMP [17]. However, reports of small ef- 
fects of FSK on cGMP have also appeared [18,19]. 
We confirmed this with the rat pinealocyte and also 
found that the cGMP response to FSK is strongly 
potentiated by an a]-adrenergic ~ [Ca2+]i 
mechanism involving PKC. 
2. EXPERIMENTAL 
2.1. Materials 
Phenylephrine (PE), propranolol, nifedipine, diolein, dioc- 
tanoylglycerol, and A23187 were obtained from Sigma (St. 
Louis, MO). Phorbol esters and FSK were purchased from 
Calbiochem (La Jolla, CA). All other drugs and chemicals were 
from commercial sources and of the purest grade available. An- 
tibodies for the cAMP and cGMP radioimmunoassays were 
gifts from Dr K. Catt (NICHD, NIH, Bethesda, MD). Sprague- 
Dawley rats (female, 200 g) were obtained from Charles River. 
2.2. Methods 
Pinealocytes were prepared and treated as described [6,20]. 
Drugs were dissolved in water, ethanol or dimethyl sulfoxide 
and added at less than 1 °70 of the total volume. At this concen- 
tration, ethanol or dimethyl sulfoxide has no effect on the 
cAMP and cGMP responses of pinealocytes to NE. After treat- 
ment, cells were pelleted and frozen [6]. 
The frozen cell pellet was lysed by boiling for 3 rain in 5 mM 
acetic acid (100 /zl). The preparation was then centrifuged 
(12000 x g, 10 min), and the supernatant used for determina- 
tions of cAMP and cGMP by radioimmunoassay [6,21] and 
protein [22]. 
Triplicate samples were used for each group; each sample was 
analyzed in duplicate and the average of duplicate determina- 
tions was used to generate the mean + SE of cyclic nucleotides 
in each treatment group. Data were analyzed by Bartlett's test 
for heterogeneity and Duncan's multiple range test [23]. 
3. RESULTS 
3.1. Effect of FSK on cAMP and cGMP 
accumulation 
FSK treatment increased both cAMP and cGMP 
in a time- and concentration-dependent manner 
(fig. 1); the largest response to FSK alone was about 
10-fold, which represents about 10% of the max- 
imal responses normally seen with NE [6]. Re- 
sponses of this magnitude are similar to the partial 
responses elicited by agents which are thought to 
stimulate adenylyl and guanylyl cyclase activities 
via an action on Gs, the GTP-binding regulatory 
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Fig. 1. FSK stimulation of cAMP and cGMP accumulation i rat 
pinealocytes. The absence of an error bar indicates that SE fell 
within the symbol. (A,B) Concentration-response studies in 
which cells were incubated for 15 rain with the indicated concen- 
tration of FSK. (C,D) Time-course studies in which pinealocytes 
were incubated for 0-30 min with FSK (100/~M). The arrow in- 
dicates when FSK was added. 
protein; these agents include the /~-adrenergic 
agonist isoproterenol (ISO), vasoactive intestinal 
peptide (VIP), and cholera toxin (CT) [6,10, 
24-28]. 
3.2. Effect of phenylephrine(PE) on cAMP and 
cGMP accumulation i FSK treated 
pinealocytes 
Maximal cAMP and cGMP responses can be 
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Fig.2. Effect of phenylephrine or A23187 on cAMP and cGMP 
accumulation i FSK (100/~M)-treated pinealocytes. Pineal- 
ocytes were incubated as indicated for 15 rain. (A,B) Cells were 
treated with FSK and the indicated concentrations of phenyl- 
ephrine; propranolol (10/zM) was present to block possible ~'- 
adrenergic effects. (C,D) Cells were treated with FSK and the in- 
dicated concentrations of A23187. 
produced by treatment with the mixed tel,fl- 
adrenergic agonist NE or by treatment with either 
ISO, VIP or CT in combination with trl-adrenergic 
agonists, such as PE [6,10,24-28]. PE also poten- 
tiates stimulation of cAMP by FSK [14]. We were 
interested in determining whether a~-adrenergic a - 
tivation could potentiate FSK stimulation of 
cGMP accumulation. Alone, PE had only a small 
effect on cGMP (fig.2A,B). However, it poten- 
tiated FSK stimulation of cGMP in a concentra- 
tion-dependent manner. This observation is con- 
sistent with the interpretation that FSK shares a 
common mechanism of action in cGMP regulation 
with ISO, VIP and CT [29]. 
3.3. Effect ofA23187 or K ÷ on cAMP and cGMP 
accumulation in FSK treated pinealocytes 
PE is thought to potentiate #-adrenergic, VIP 
and CT stimulation of pineal cyclic nucleotides by 
increasing Ca 2÷ influx, thereby elevating [Ca2+]i 
about 4-fold [9,30]. To determine whether the ef- 
fects of FSK were potentiated by elevating [Ca2+]i, 
we treated cells with FSK and either A23187 or K ÷. 
The former'is a Ca 2÷ ionophore. The latter elevates 
[Ca2+]i indirectly by depolarizing the cell; this 
opens voltage-sensitive Ca 2÷ channels. In these 
studies A23187 (fig.2C,D) or K ÷ (fig.3A,B) poten- 
tiated FSK stimulation of both cAMP and cGMP 
accumulation. 
The issue of whether K + was acting on the cGMP 
response through Ca 2+ was further investigated by 
determining if nifedipine (NIF) could block this ef- 
fect. NIF blocks Ca 2+ influx through some voltage- 
sensitive Ca 2+ channels [31]; in the pinealocyte it
inhibits K+-induced increases in [Ca2+]i and 
K÷-induced potentiation of cAMP and cGMP 
responses to ISO, VIP or CT [9,30]. In the present 
experiments (table 1, expt I) NIF blocked the 
K÷-induced potentiation of FSK stimulation of 
cAMP and cGMP accumulation. This indicates 
that K ÷ was probably acting through Ca +. These 
results are consistent with the interpretation that 
the cGMP response to FSK is potentiated by PE ac- 
ting via a Ca 2÷ mechanism. 
3.4. Effect o f  K ÷ or 4#-phorbol 12-myristate 
13-acetate (PMA) on cAMP and cGMP 
accumulation i  FSK treated pineaiocytes 
Ca 2+ is known to potentiate stimulation of 
pineal cyclic nucleotides in part by translocation of 
PKC [7,8,32]; in the case of cGMP potentiation, 
Ca 2÷ activates another process [10]. We studied the 
role of PKC using ceils treated with concentrations 
of FSK and K + (15 mM) which alone produced on- 
ly a small elevation of cAMP and cGMP 
(fig.3C,D). In the presence of FSK alone, the PKC 
activator PMA potentiated FSK stimulation of 
cAMP as reported in [14]; in contrast, cGMP was 
not influenced. However, in the presence of K + (15 
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Fig.3. Effect of K ÷ or PMA on cAMP and cGMP accumulation 
in FSK (100/zM)-treated pinealocytes. (A,B) Cells were treated 
with FSK and the indicated concentrations of K ÷. (C,D) Cells 
were treated with FSK and the indicated concentration f PMA 
with K ÷ (closed symbols) and without (open symbols) K ÷ (15 
mM). 
raM) and FSK,  PMA produced  a 
concent ra t ion -dependent  potent ia t ion  o f  the 
s t imulat ion  o f  cGMP (f ig.3D).  Two other  PKC ac- 
t ivators ,  4#-phorbo l  12,13-dibutyrate (PDBu)  and 
d ioctanoy lg lycero l  (DC8)  [33] also potent ia ted  
FSK  + K + s t imulat ion  o f  cAMP and cGMP ac- 
cumulat ion  (table 1, expt I I) .  In  contrast ,  re lated 
compounds  which do not  ac t ivate  pineal  PKC,  viz. 
4~-phorbo l  12,13-d idecanoate (PDD)  and dio l ien 
(D IOL)  [33], d id not  cause potent ia t ion  (table 1, 
Table 1 
Effect of selected agents on K + potentiation of FSK-stimulated 
cAMP and cGMP accumulation i pinealocytes 
Expt Treatment cAMP cGMP 
(pmol/mg protein) 
I Control 21.1 + 1.6 1.4 + 0.8 
FSK 169 _+ 4.2 14.3 _+ 0.7 
+ K + (40 mM) 604 ± 37.3 a 124 ± 12.7 a
+ K+(40 raM) + 
N1F 189 ± 13.1 b 16.4 ± 2.1 b 
+ NIF 174 ± 6.5 15.7 ± 2.0 
NIF 26.6 ± 3.2 1.7 ± 0.3 
K+(4OmM) 29.3 ± 2.4 2.1 ± 0.4 
Control 18.3 ± 0.4 2.1 ± 0.3 
FSK 173 _+ 16.9 15.6 _+ 2.8 
FSK + K + 
(15 mM) 211 ± 15.4 21.2 +_ 0.91 
+ PMA 2070 +_ 85 b 272 ± 16.4 b 
+ PDBu 1530 + 36 b 250 ± 18.4 b 
+ DC8 1000 ± 63 b 116 ± 6.8 b 
+ PDD 179 ± 21.3 23.0 + 1.52 
+ DIOL 189 + 15.6 17.0 + 3.3 
a Significantly different from the FSK-treated group (p < 0.05) 
b Significantly different from the corresponding FSK + 
K+-treated group (p< 0.05) 
Expt I: NIF (1 #M) was added to some tubes and 5 min later FSK 
(100/~M) and K+(40 raM) were added as indicated. 15 rain later 
the cells were pelleted and frozen. Expt II: FSK (100/~M) K+ (15 
raM), PMA (0.1 #M), PDBu (0.1 #M), DC8 (100 #g/ml), PDD 
(0.1/~M) and DIOL (100/~g/ml) were added as indicated. 15 rain 
later the cells were pelleted and frozen 
expt I I) .  These f indings indicate that  PKC is involv-  
ed in the PE  ~ Ca  2+ mechan ism which potent iates 
FSK  s t imulat ion  o f  cGMP accumulat ion .  
4. D ISCUSSION 
The  results o f  this series o f  exper iments  conf i rm 
prev ious  reports  that  FSK  can elevate cGMP 
[18,19], and demonst ra te  for  the first t ime that  ef- 
fects o f  FSK  on cGMP can be marked ly  enhanced  
by t reatments  which  elevate [Ca2+]i and t rans locate  
PKC.  This  leads to the suggest ion that  ef fects o f  
FSK  on  cGMP accumulat ion  in other  t issues might  
be unmasked by cot reatment  wi th appropr ia te  
agents;  such a strategy might  reveal  the presence in 
these tissues o f  b iochemica l  AND gates which 
phys io log ica l ly  regulate cGMP product ion .  
_A l though there is c lear ev idence for  a FSK  
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cGMP link, the precise mechanism through which 
FSK acts to elevate cGMP is not clear f rom these 
studies. One explanat ion is that the cGMP 
response is secondary to that of  cAMP.  This seems 
unl ikely because we have found that t reatment with 
0.1 mM dibutyryl  cAMP does not elevate cGMP 
signif icantly (unpubl ished).  Another  possibi l i ty is 
that the cGMP response is independent of  cAMP,  
and that guanylyl  cyclase, like adenylyl  cyclase, is 
act ivated by FSK. Other evidence of  a similarity is 
that in the pinealocyte both enzymes appear  to be 
regulated by Gs and PKC-dependent  mechanisms 
in the pinealocyte [10,28], are substrates for PKC 
[12,23] and act on similar substrates to produce 
similar products.  Accordingly ,  we suspect that 
pineal  adenylyl  and guanylyl  cyclases belong to the 
same gene family.  
Based on the f indings here and elsewhere 
[18,19], it seems prudent  o suspect hat any effect 
of  FSK treatment may in part  reflect an act ion of  
cGMP.  For  example,  very early reports on FSK 
describe b lood pressure lowering effects [34-36]. 
Perhaps  these effects reflect an act ion of  cGMP,  
which is thought to be involved in the act ion of  a 
well establ ished and widely used b lood pressure 
lowering agent, sodium nitroprusside.  
F inal ly,  it should be added that a number of  con- 
vincing reports of  cAMP- independent  effects of  
FSK have appeared [37-39]. In view of  these 
reports and the effects of  FSK on cGMP,  it is now 
apparent  that the FSK = cAMP equat ion must be 
used cautiously.  
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